PL2200588T3 - Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania - Google Patents

Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania

Info

Publication number
PL2200588T3
PL2200588T3 PL08832858T PL08832858T PL2200588T3 PL 2200588 T3 PL2200588 T3 PL 2200588T3 PL 08832858 T PL08832858 T PL 08832858T PL 08832858 T PL08832858 T PL 08832858T PL 2200588 T3 PL2200588 T3 PL 2200588T3
Authority
PL
Poland
Prior art keywords
compositions
preparation
active compounds
lipophilic active
lipophilic
Prior art date
Application number
PL08832858T
Other languages
English (en)
Inventor
Galia Temtsin Krayz
Maryana Averbuch
Larisa Gitis
Ilya Zelkind
Original Assignee
Solubest Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40340343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2200588(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solubest Ltd. filed Critical Solubest Ltd.
Publication of PL2200588T3 publication Critical patent/PL2200588T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PL08832858T 2007-09-25 2008-09-25 Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania PL2200588T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97506607P 2007-09-25 2007-09-25
US97504507P 2007-09-25 2007-09-25
PCT/IL2008/001294 WO2009040818A1 (en) 2007-09-25 2008-09-25 Compositions comprising lipophilic active compounds and method for their preparation
EP08832858.8A EP2200588B1 (en) 2007-09-25 2008-09-25 Compositions comprising lipophilic active compounds and method for their preparation

Publications (1)

Publication Number Publication Date
PL2200588T3 true PL2200588T3 (pl) 2019-09-30

Family

ID=40340343

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08832858T PL2200588T3 (pl) 2007-09-25 2008-09-25 Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania

Country Status (12)

Country Link
US (2) US9254268B2 (pl)
EP (2) EP2601935A1 (pl)
AU (1) AU2008303129B2 (pl)
CA (1) CA2700426C (pl)
DK (1) DK2200588T3 (pl)
ES (1) ES2731881T3 (pl)
HR (1) HRP20191104T1 (pl)
HU (1) HUE043897T2 (pl)
IL (1) IL204711A0 (pl)
PL (1) PL2200588T3 (pl)
SI (1) SI2200588T1 (pl)
WO (1) WO2009040818A1 (pl)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20080076743A1 (en) 2006-08-03 2008-03-27 Nitec Pharma Ag Delayed-Release Glucocorticoid treatment of Rheumatoid Disease
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US9254268B2 (en) 2007-09-25 2016-02-09 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
EP2433124B1 (en) * 2009-05-19 2017-03-01 Vivia Biotech S.L. Methods for providing personalized medicine tests ex vivo for hematological neoplasms
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
US20120076838A1 (en) * 2009-05-27 2012-03-29 Samyang Biopharmaceuticals Corporation Poorly soluble drug containing microsphere with improved bioavailabilty and method of preparing the same
CN101637473B (zh) * 2009-06-19 2011-08-17 山东大学 一种含雷洛昔芬的药物配伍组合及其应用
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PL2459176T3 (pl) 2009-07-31 2018-02-28 Grünenthal GmbH Sposób krystalizacji i biodostępność
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
ES2649022T3 (es) 2009-11-20 2018-01-09 Tonix Pharma Holdings Limited Procedimientos y composiciones para tratar los síntomas asociados con el trastorno de estrés postraumático con ciclobenzaprina
GR1007244B (el) * 2010-01-14 2011-04-21 Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδος, Εμπορια Φαρμακων, Ποσιμα διαλυματα φλουκοναζολης
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
ES2664793T3 (es) 2010-03-12 2018-04-23 Berg Llc Formulaciones intravenosas de coenzima Q10 (CoQ10) y métodos de uso de las mismas
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
US20130039864A1 (en) * 2010-04-23 2013-02-14 Francois Ravenelle Non-Intravenous Dosage Form Comprising Solid Formulation of Liquid Biologically Active Agent and Uses Thereof
GB201007290D0 (en) * 2010-04-30 2010-06-16 R5 Pharmaceuticals Ltd Pharmaceutical powder compositions
GB201008043D0 (en) * 2010-05-14 2010-06-30 Unilever Plc Compositions
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
CN102008435B (zh) * 2010-08-25 2012-01-11 齐鲁动物保健品有限公司 一种禽用癸氧喹酯口服混悬液及其制备方法
CN103079547B (zh) 2010-09-02 2015-01-21 日本化药株式会社 药物-嵌段共聚物复合物及含有它的药品的制造方法
LT2637668T (lt) 2010-11-04 2016-09-12 Albireo Ab Ibat inhibitoriai kepenų ligoms gydyti
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
EP2661254B1 (en) 2011-01-05 2017-08-02 Hospira, Inc. Spray drying vancomycin
WO2012114196A1 (pt) * 2011-02-25 2012-08-30 Nanocare Technologies, Inc. Formulação farmacêutica compreendendo compostos da família dos jasmonatos
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
CN107970209B (zh) 2011-04-28 2020-10-30 普拉福姆五金器具第二有限公司 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法
US20130150330A1 (en) * 2011-06-13 2013-06-13 University Of Kansas Decoquinate prodrugs
MX351781B (es) 2011-06-17 2017-10-30 Berg Llc Composiciones farmaceuticas inhalables.
DE102011051308A1 (de) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Herstellungsverfahren und Arzneiform
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
BR112014006153A2 (pt) 2011-09-16 2020-12-01 Nanocare Technologies, Inc. composição farmacêutica, e, método para tratar um distúrbio
US9949992B2 (en) 2011-11-16 2018-04-24 Duke University Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
IN2012DE00674A (pl) 2012-03-07 2015-08-21 Nat Inst Of Pharmaceutical Education And Res Niper
CN102579395B (zh) * 2012-03-30 2013-10-30 江苏万禾制药有限公司 一种硫辛酸胶囊及其制备工艺和用途
RU2765231C2 (ru) 2012-04-04 2022-01-26 Интервет Интернэшнл Б.В. Мягкие жевательные фармацевтические продукты
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
CN103539967B (zh) * 2012-07-16 2017-10-20 上海市肿瘤研究所 核壳结构聚合物/纳米金复合纳米材料及其制备方法和应用
WO2014042598A1 (en) * 2012-09-17 2014-03-20 National University Of Singapore Drug therapy for cancer, including multiple myeloma
US20140127385A1 (en) * 2012-11-04 2014-05-08 Ingredient Innovations International Stable Aqueous Dispersions of Poorly Soluble Crystalline Nutrients
RU2018141241A (ru) 2012-11-30 2019-01-24 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
DE102012113098A1 (de) * 2012-12-27 2014-07-03 Hennig Arzneimittel Gmbh & Co. Kg Monolithische Arzneiform zur modifizierten Freisetzung einer Wirkstoffkombination
WO2014113495A1 (en) 2013-01-15 2014-07-24 The Trustees Of Columbia University In The City Of New York Activation or reactivation of ache
BR102013021210B1 (pt) * 2013-01-25 2015-12-01 Fundação Universidade Fed De São Carlos processo de obtenção de nanopartículas biopoliméricas contendo óleo e extratos de azadirachta indica a. juss (neem), nanopartículas biopoliméricas e micropartículas em pó
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
ES2681952T3 (es) 2013-03-15 2018-09-17 SpecGx LLC Forma farmacéutica sólida disuasoria del abuso de liberación inmediata con puntaje funcional
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
RS60015B1 (sr) * 2013-03-15 2020-04-30 Tonix Pharma Holdings Ltd Eutektičke formulacije ciklobenzapirin hidrohlorida i manitola
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9511341B2 (en) 2013-08-30 2016-12-06 Sunny Pharmtech Inc. Method for preparing acetazolamide sodium powder
HUE034490T2 (en) 2013-09-16 2018-02-28 Astrazeneca Ab Therapeutic polymer nanoparticles and methods for their preparation and use
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
WO2015145459A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
CN103877064B (zh) * 2014-04-11 2016-04-27 白玲强 一种非诺贝特胶囊剂及其制备工艺
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
HUE065006T2 (hu) 2014-07-03 2024-04-28 SpecGx LLC Nem-cellulóz poliszacharidokat tartalmazó, visszaélés-gátló, azonnali felszabadulású készítmények
CN104146968B (zh) * 2014-07-23 2017-01-18 国药集团容生制药有限公司 注射用甲泼尼龙琥珀酸钠及其制备方法
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
CN104188975A (zh) * 2014-08-20 2014-12-10 冷敏 一种治疗压疮的西药组合物、乳膏及其乳膏的制备方法
SG11201701995PA (en) * 2014-09-18 2017-04-27 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
AU2015317358A1 (en) 2014-09-19 2017-04-27 Board Of Regents, The University Of Texas System Methods of preparing extrudates
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
WO2016109779A1 (en) 2014-12-31 2016-07-07 Nanocare Technologies, Inc. Jasmonate derivatives and compositions thereof
BR112017019364B1 (pt) * 2015-03-12 2023-03-21 Dupont Nutrition Usa, Inc Dispersões sólidas e forma de dosagem de fármacos
CA2987517A1 (en) * 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
WO2016210003A2 (en) 2015-06-22 2016-12-29 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
JP6856631B2 (ja) * 2015-09-16 2021-04-07 ディーエフビー ソリア リミテッド ライアビリティ カンパニー 薬物ナノ粒子の送達およびその使用法
CN109195584A (zh) * 2015-09-16 2019-01-11 国家科学研究中心 用于治疗恶性肿瘤和/或防止肿瘤复发的胶凝组合物
WO2017072774A1 (en) * 2015-10-29 2017-05-04 Solubest Ltd Pharmaceutical compositions for transmucosal delivery
CN106631869A (zh) * 2015-12-06 2017-05-10 宁夏际华环境安全科技有限公司 一种二硝托胺脂生产工艺
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3036356A1 (en) 2016-09-09 2018-03-15 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen
WO2018067959A1 (en) 2016-10-07 2018-04-12 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
EP3595633B1 (en) 2017-03-15 2023-07-05 DFB Soria, LLC Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
US10555899B2 (en) 2017-06-05 2020-02-11 Piedmont Animal Health, Llc Long-acting non-aqueous injectable formulations and use thereof
EP3658123A4 (en) 2017-07-24 2021-04-28 Acryspharm LLC PHARMACEUTICAL COMPOSITIONS WITH A HIGH DRUG LOAD
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
CN107854424A (zh) * 2017-10-30 2018-03-30 沈小玲 一种阿奇霉素眼用原位凝胶及其制备方法
CN111315236A (zh) * 2017-11-03 2020-06-19 帝斯曼知识产权资产管理有限公司 新递送系统
WO2019116091A1 (en) 2017-12-11 2019-06-20 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
US10799453B2 (en) 2018-04-11 2020-10-13 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
MY209425A (en) 2018-06-20 2025-07-08 Albireo Ab Crystal modifications of odevixibat
MX2021001364A (es) 2018-08-03 2021-04-13 Ptc Therapeutics Inc Formas farmaceuticas orales biodisponibles.
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
CN109674767A (zh) * 2019-01-18 2019-04-26 安徽瑞达健康产业有限公司 一种含有番茄红素的微丸及其制备方法
EP3884930A1 (en) * 2020-03-23 2021-09-29 Bayer AG Nano-dry-melting
EP3943071B1 (de) 2020-03-31 2025-06-18 Zurab Durmischchanowitch Khinikadze Zusammensetzung, enthaltend natürliche lipophile verbindungen, verwendung der zusammensetzung und verfahren zur herstellung der zusammensetzung
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
CN112190567B (zh) * 2020-11-09 2022-03-11 山东华辰制药有限公司 一种伊维菌素缓释微球的制备方法及应用
CN112999196B (zh) * 2021-03-03 2023-04-28 西安医学院 用于长效稳定释放的吗替麦考酚酯纳米制剂及其制备方法
CN113133989B (zh) * 2021-03-09 2023-04-25 西安医学院 一种用于抗结核药物利福平的长效制剂及制备方法
US11878025B2 (en) 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone
CN115531306B (zh) * 2022-05-12 2024-03-26 南京锐志生物医药有限公司 一种注射用左奥硝唑衍生物乳状制剂及其制备方法
CN115998695A (zh) * 2022-09-09 2023-04-25 青海大学 一种阿苯达唑盐和聚合物复合物片剂及其制备方法和用途
JP2025536556A (ja) 2022-10-25 2025-11-07 ヴェラダーミクス インコーポレイテッド 放出調節ミノキシジル用組成物および使用方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5208037A (en) 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
DK0965591T3 (da) 1991-06-21 2002-11-18 Boehringer Ingelheim Pharma Fremgangsmåde til fremstilling af (S)-3-methyl-1-(2-piperidino-phenyl)-1-butylamin
ATE240734T1 (de) 1995-07-26 2003-06-15 Kyowa Hakko Kogyo Kk Zubereitung von xanthinderivaten als feste dispersion
WO1997006787A2 (en) * 1995-08-17 1997-02-27 Dyer, Alison, Margaret Controlled release products
DE19531277A1 (de) * 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
CA2261456A1 (en) 1998-02-23 1999-08-23 F. Hoffmann-La Roche Ag Preparation of a finely divided pulverous carotenoid preparation
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
ATE464900T1 (de) * 1998-03-26 2010-05-15 Astellas Pharma Inc Retardpräparat mit makroliden wie tacrolimus
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
US6730322B1 (en) * 1998-04-30 2004-05-04 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
MXPA01012225A (es) 1999-05-28 2002-08-12 Abbott Lab Formulaciones novedosas que comprenden agentes reguladores de lipido.
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2002024169A1 (en) 2000-09-20 2002-03-28 Skyepharma Canada Inc. Spray drying process and compositions of fenofibrate
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AR033711A1 (es) 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
BR0210520A (pt) * 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
US8071133B2 (en) * 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
CA2461890C (en) * 2001-09-28 2010-12-14 Solubest Ltd. Water soluble nanoparticles of hydrophilic and hydrophobic active materials
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
MXPA04007438A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
EP1531799A1 (en) 2002-06-10 2005-05-25 Elan Pharma International Limited Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
EP1521571A1 (en) 2002-07-04 2005-04-13 Janssen Pharmaceutica N.V. Solid dispersion comprising two different polymer matrixes
WO2004069138A2 (en) 2003-02-03 2004-08-19 Novartis Ag Pharmaceutical formulation
ES2376238T3 (es) * 2003-08-29 2012-03-12 Veloxis Pharmaceuticals A/S Composiciones de liberación modificada comprendiendo tacrolimus.
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
JP5069001B2 (ja) 2003-10-10 2012-11-07 ベロクシス ファーマシューティカルズ エー／エス フィブラートを含む固体投与形態
JP2007508249A (ja) 2003-10-10 2007-04-05 ライフサイクル ファーマ アクティーゼルスカブ フィブラートとスタチンを含む固体剤型
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US20070148232A1 (en) * 2003-12-31 2007-06-28 Pfizer Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs and poloxamers, and stabilizing polymers
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
WO2006037346A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and simvastatin
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
WO2006060817A1 (en) 2004-12-03 2006-06-08 Abbott Laboratories Pharmaceutical compositions
KR20070116581A (ko) 2004-12-15 2007-12-10 엘란 파마 인터내셔널 리미티드 나노입자형 타크롤리무스 제제
EP1833877A2 (en) * 2004-12-21 2007-09-19 Baxter International Inc. (polyalkoxy)sulfonate surface modifiers
US20060222707A1 (en) * 2005-03-30 2006-10-05 Lerner E I Formulations of fenofibrate
AU2006269225B2 (en) 2005-07-07 2011-10-06 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
EP1774971A1 (en) 2005-10-14 2007-04-18 Advanced in Vitro Cell Technologies, S.L. Chitosan and heparin nanoparticles
EP1834635B1 (en) 2006-03-13 2011-07-06 Advanced in Vitro Cell Technologies, S.L. Stable nanocapsule systems for the administration of active molecules
WO2007141806A1 (en) 2006-06-02 2007-12-13 Jubilant Organosys Ltd Pharmaceutical formulations comprising oxcarbazepine and methods thereof
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US7569612B1 (en) * 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
US9254268B2 (en) 2007-09-25 2016-02-09 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation

Also Published As

Publication number Publication date
WO2009040818A1 (en) 2009-04-02
US20160220505A1 (en) 2016-08-04
HUE043897T2 (hu) 2019-09-30
SI2200588T1 (sl) 2019-08-30
AU2008303129B2 (en) 2013-08-01
DK2200588T3 (da) 2019-07-01
CA2700426A1 (en) 2009-04-02
EP2200588B1 (en) 2019-03-20
US9254268B2 (en) 2016-02-09
HRP20191104T1 (hr) 2019-09-20
EP2601935A1 (en) 2013-06-12
AU2008303129A1 (en) 2009-04-02
CA2700426C (en) 2017-10-31
EP2200588A1 (en) 2010-06-30
WO2009040818A9 (en) 2010-05-20
ES2731881T3 (es) 2019-11-19
US20090098200A1 (en) 2009-04-16
IL204711A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
PL2200588T3 (pl) Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
IL207519A (en) Pesticides and processes
HRP20181837T1 (hr) Farmaceutski pripravci koji sadrže zeljezov oksi-hidroksid
AP3106A (en) Antiparisitic dihydroazole compounds and compositions comprising same
IL213706A0 (en) Stable insecticide compositions and methods for producing same
IL217955A (en) Pesticides and pesticides containing them
IL195524A0 (en) Nanoparticulate posaconazole formulations
ZA200806842B (en) Imidazole-based compounds,compositions comprising them and methods of their use
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
IL216171A (en) Lipidic Compound, Method for Preparing the Compound, Pharmaceutical and Lipid Preparations Containing Their Composition and Uses
HUE063083T2 (hu) Nilotinibet vagy sóját tartalmazó gyógyszerészeti készítmények
EP2011482A4 (en) SOLID PREPARATION FOR ORAL APPLICATION
IL211018A (en) Inhibitors, processes for making them, medicinal preparations containing them and their use
IL200885A (en) A history of mannich-based compounds and pharmacological preparations including them
EP2214645A4 (en) LIPOSOMAL VANCOMYCIN PREPARATIONS
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
IL194366A0 (en) Solid dosage formulations
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
IL208788A (en) Pharmacy-based formulation
IL203064B (en) A pharmaceutical preparation containing compound 11 - deoxy - prostaglandin and a method for stabilizing the compound
IL212171A (en) 1-Phenylpyrol compounds, pharmaceuticals containing them and their use
EP2335698A4 (en) SOLID PHARMACEUTICAL PREPARATION CONTAINING ACTIVE INGREDIENTS SEPARATED BY AN INTERNAL FRONTIER
ZA200907150B (en) New compositions and methods for cell killing
GB0902648D0 (en) Pharmaceutical compounds and compositions
IL206936A0 (en) 2-amino-2-phenylalkanol derivatives, preparation thereof and pharmaceutical compositions containing same